Salud financiera de hoja de balance de Camurus

Salud financiera controles de criterios 6/6

Camurus tiene un patrimonio de accionistas total de SEK1.5B y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK1.9B y SEK414.8M respectivamente. El BAIT de Camurus es de SEK533.4M, por lo que su ratio de cobertura de intereses es de -22.8. Tiene efectivo e inversiones a corto plazo que ascienden a SEK1.2B.

Información clave

Ratio deuda-patrimonio

kr0

Deuda

Ratio de cobertura de intereses	-22.9x
Efectivo	kr2.27b
Patrimonio	kr2.65b
Total pasivo	kr415.07m
Activos totales	kr3.06b

Actualizaciones recientes sobre salud financiera

Recent updates

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

May 02

Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Apr 19

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Feb 22

With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Feb 17

Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected

Dec 20

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Nov 11

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Feb 22

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Apr 30

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Dec 09

Companies Like Camurus (STO:CAMX) Can Afford To Invest In Growth

Sep 09

Companies Like Camurus (STO:CAMX) Can Afford To Invest In Growth

Jun 10

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK1.6B) de CAMX superan a sus pasivos a corto plazo (SEK368.6M).

Pasivo a largo plazo: Los activos a corto plazo de CAMX (SEK1.6B) superan a sus pasivos a largo plazo (SEK46.2M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: CAMX está libre de deudas.

Reducción de la deuda: CAMX no ha tenido ninguna deuda en los últimos 5 años.

Cobertura de la deuda: CAMX no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: CAMX no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.

Salud financiera de hoja de balance de Camurus

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Companies Like Camurus (STO:CAMX) Can Afford To Invest In Growth

Companies Like Camurus (STO:CAMX) Can Afford To Invest In Growth

Recent updates

First quarter 2024 earnings released: EPS: kr1.36 (vs kr1.06 in 1Q 2023)

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Camurus AB (Publ) Announces Board Resignations

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB (Publ) Announces FDA Acceptance of NDA Submission for Oclaiz™ for Treatment of Acromegaly

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Consensus EPS estimates fall by 39%

With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB Provides Earnings Guidance for the Full Year 2024

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

Camurus AB (Publ) Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease

Investor sentiment deteriorates as stock falls 15%

Price target increased by 8.2% to kr550

Camurus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.09 billion.

Camurus AB (publ) Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly

Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected

President exercised options to buy kr86m worth of stock.

Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors

Price target increased by 16% to kr471

Investor sentiment improves as stock rises 20%

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Camurus AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.1% to kr351

Camurus AB (Publ) Raises Earnings Guidance for the Year 2023

Camurus AB (publ), Annual General Meeting, May 08, 2024

Insider recently sold kr295k worth of stock

Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn

Camurus AB (Publ) Provides Earnings Outlook for the Year 2023

New major risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot (Cam2029) in Patients with Acromegaly

Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly

President recently sold kr23m worth of stock

Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder

Consensus EPS estimates increase by 21%

Consensus EPS estimates increase by 25%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (Publ) Elects Erika Söderberg Johnsson as Board Member

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Price target decreased by 7.3% to kr287

Third quarter 2022 earnings released: EPS: kr0.63 (vs kr0.11 loss in 3Q 2021)

Consensus EPS estimates increase by 17%

Camurus AB (Publ) Provides Earnings Guidance for the Year 2023

Consensus forecasts updated

Camurus Announces PDUFA Date for Brixadi NDA for the Treatment of Opioid Use Disorder in the US

Forecast to breakeven in 2022

Price target increased to kr305

Camurus AB (Publ) Provides Earnings Guidance for the Year 2022

Price target increased to kr283

Camurus AB (publ), Annual General Meeting, May 10, 2023

Camurus AB (publ) to Report Fiscal Year 2022 Final Results on Mar 30, 2023

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Camurus AB (Publ) Raises Operating Result Guidance for the Full Year 2022

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX).

Vice President exercised options and sold kr178k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Camurus AB (Publ) Elects Stefan Persson as New Board Member

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Full year 2021 earnings: EPS and revenues miss analyst expectations

Camurus AB (Publ) Provides Earnings Guidance for the Fiscal Year 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (Publ) Provides Earnings Guidance for the Fiscal Year 2022

Camurus Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Pants with Genetic Obesity Disoisorder

Forecast breakeven date pushed back to 2022

Camurus AB Announces Braeburn Receives New Complete Response Letter for Brixadi in the US

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Insider recently sold kr392k worth of stock

The European Medicines Agency Accepts Camurus's Application to Extend the Buvidal Indication to Include Treatment of Chronic Pain